Incyte Reports 20% Q4 Revenue Growth to $780M, Launches Two Phase III Trials
Jakafi sales climbed 20% in Q4 2025, driving Incyte's overall revenue to $780 million. The company also kicked off Phase III studies for its JAK1 inhibitor itacitinib and FGFR inhibitor pemigatinib.
1. Q4 2025 Financial Performance
Incyte posted $780 million in revenue for Q4 2025, a 20% increase year-over-year. The growth was primarily driven by a 20% rise in Jakafi sales across its myelofibrosis and graft-versus-host disease indications.
2. Pipeline Advancement
The company initiated Phase III trials for its JAK1 inhibitor itacitinib in acute GVHD and FGFR inhibitor pemigatinib in cholangiocarcinoma. Management expects initial clinical data by late 2026.
Related News
JEPI
Active ETFs Shift Holdings Daily, Provide Downside Protection, Charge 0.4%-1% Fees
JEPI•
NVDA
Nvidia posts US$81.6B Q1 revenue, forecasts US$91B for Q2
NVDA•
BLTE
Belite Bio Begins FDA NDA Rolling Submission, Q1 Loss Widens on $15.7M R&D
BLTE•
DE
Menon Bearings Posts 23% Revenue Gain, 51 New Parts for Deere Supply
DE•
NVDA
Nvidia Tops $91B Sales Forecast, Boosts Dividend and Buyback Program
NVDA•
Sources
F